Compare · HRMY vs NVO
HRMY vs NVO
Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRMY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 114.0x HRMY ($1.96B).
- Over the past year, HRMY is down 4.2% and NVO is down 21.8% - HRMY leads by 17.6 points.
- HRMY has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 23 for HRMY).
- Company
- Harmony Biosciences Holdings Inc.
- Novo Nordisk A/S
- Price
- $33.74+0.66%
- $50.31-2.25%
- Market cap
- $1.96B
- $222.81B
- 1M return
- -0.27%
- +15.47%
- 1Y return
- -4.17%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 23
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HRMY
- Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
- Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
- Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
- SEC Form 144 filed by Harmony Biosciences Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S